Autoresearch: As of 19 Sep 2026, did Germany back down on April 2026 revenue-tied drug-price cuts after the USTR Section 301 initiation? Is the 22 Sep hearing still on? Did Lilly confirm a German investment cut in its own words?

Generated by /autoresearch on 2026-09-19. Synthesized across 3 rounds from USTR/Federal Register primaries and German-law / Lilly-spokesperson secondaries. See Provenance. Context: vault/projects/stock-market Research-only. No buy/sell/size.

Summary

Germany did not restore the pre-April status quo. The Bundestag/Bundesrat passed GKV-BStabG on 10 Jul 2026: the draft’s dynamic/variable rebate (industry-modelled toward ~20% by 2030) was struck, and a fixed manufacturer rebate of 15.5% (7% + 8.5 pp) applies from 1 Jan 2027. That is a formula back-down and a rate tightening. Lilly, via spokesperson to Fierce, cut the planned €2.3 billion Alzey project “by 50% or more” and put remaining capacity on hold until “stable, predictable” conditions return — Step 2 is now company-attributed, still not an 8-K. USTR-2026-0463/0464 remain live; written comments were due 10 Aug; the public hearing is still noticed for 22 Sep 2026, 10:00 a.m. at the ITC (three days after this pass). Causal “301 made Berlin fold” is not established — Reuters’ “rethinking” print sat around mid-June, overlapping the 18 Jun initiation. Step 4 stays open.

Findings

The 301 docket and calendar are unchanged

USTR initiated “Germany’s Persistent Underpayment for Innovative Pharmaceutical Products” on 18 Jun 2026; Federal Register 24 Jun 2026 (FR 2026-12671; USTR FRN PDF; USTR press release). Dockets USTR-2026-0463 (comments) and USTR-2026-0464 (appear). Hearing: 22 Sep 2026, 10:00 a.m., USITC main hearing room; may continue 23 Sep. No retrieved cancellation or postponement as of 19 Sep. The FRN’s investigated practices include “supplemental discounts in exchange for confidentiality” and “mandatory variable rate rebates.”

GKV-BStabG: variable formula out, 15.5% fixed in

Access Infinity / pharmazie.com / Fierce / Covington all describe the same enacted bargain: Bundestag 319–286 on 10 Jul, Bundesrat the same day; dynamic rebate dropped; total manufacturer discount 15.5% from 1 Jan 2027; AMNOG guardrail repeal and a statutory volume/growth fallback (1.5% per €100m turnover + 1.7% growth factor) remain tightening tools (Access Infinity; pharmazie.com; Fierce 10 Jul; Covington / Inside EU Life Sciences 29 Jul). Primary BGBI text was not fetched this pass (PDF/off-whitelist). Treat the 15.5% figure as multi-sourced legal-press, not a Bundesgesetzblatt quote.

This is not “Germany backed off.” It is “Germany swapped an open-ended revenue-tied escalator for a higher locked rebate.” The chain’s Step 4 rumor (“maybe Germany is going to back off”) over-predicted relief.

Lilly Alzey: company statement, not an 8-K

Fierce, citing a Lilly spokesperson: original €2.3 billion Alzey injectable site; “we can no longer commit to the full vision for Alzey and expect to reduce the scope of the project by 50% or more versus the original announcement”; remaining capacity “on hold until the Federal Government restores the stable, predictable economic framework” (Fierce). BioSpace follow-up: site still slated to open 2027 at reduced capacity; further expansion depends on “stable and predictable economic conditions” (BioSpace / Reuters recap). Boehringer cut cited at €900 million in the same Fierce piece. No Lilly SEC exhibit retrieved. Step 2 can be strengthened from podcast-only to press-quoted spokesperson; it is still not primary-filing confirmed.

Timing vs 301

Fierce: Germany “in mid-June moved to nix plans for a variable drug discount structure, Reuters reported at the time,” then passed the 15.5% package 10 Jul. USTR initiated 18 Jun. The variable-formula kill is contemporaneous with the 301, not a documented concession to the 301. Sept 22 testimony is the first on-the-record US trade proceeding that could tie them.

Contradictions and open questions

• Step 4 as written (“Germany signals a back-down”) is half-true on the formula, false on the rate. Do not tag confirmed.
• Confidentiality-conditioned 9% (the other 301 target) was not independently re-fetched as repealed.
• Lilly investment cut is attributed by Lilly to “current policy direction,” not to the 301 docket.
• Hearing is future-dated as of this file (22 Sep). If it slips or Germany files a formal USTR concession, revisit.

Provenance

Rounds run: 3 of 3. X sources: attempted; spend-cap 403. Not used. Grokipedia: not used for 2026 claims.

Web sources:

• FR 2026-12671 — official — dates, dockets, 22 Sep hearing.
• USTR FRN PDF — official.
• USTR 18 Jun release — official — variable-rebate allegation.
• Fierce Lilly/Boehringer — trade press + Lilly quote.
• Fierce Bundestag passage — 15.5%; variable nixed.
• Access Infinity / pharmazie.com / Covington — enacted-law recaps.

Generated: 2026-09-19